BiotechTube

desloratadine + desloratadine

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Urticaria

Conditions

Urticaria, Chronic Idiopathic Urticaria

Trial Timeline

Apr 1, 2003 → Apr 1, 2004

NCT ID
NCT00783354

About desloratadine + desloratadine

desloratadine + desloratadine is a approved stage product being developed by Organon for Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00783354. Target conditions include Urticaria, Chronic Idiopathic Urticaria.

What happened to similar drugs?

7 of 20 similar drugs in Urticaria were approved

Approved (7) Terminated (3) Active (11)
✅OMALIZUMABNovartisApproved
✅Levocetirizine + Levocetirizine plus HydroxyzineUCBApproved
✅Levocetirizine + DesloratadineUCBApproved
✅desloratadine + placebo + cetirizineOrganonApproved
✅Desloratadine + Cetirizine + placeboOrganonApproved
✅5-mg Desloratadine + 10-mg Desloratadine + 20-mg DesloratadineOrganonApproved
✅DesloratadineOrganonApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00783354ApprovedCompleted

Competing Products

20 competing products in Urticaria

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
CT-P39 + EU-approved XolairCelltrionPhase 3
40
OmalizumabCelltrionPre-clinical
33
LY3454738 + PlaceboEli LillyPhase 2
27
AZD1981 + PlaceboAstraZenecaPhase 2
35
Benralizumab + Placebo and BenralizumabAstraZenecaPhase 2
27
LOU064NovartisPhase 3
40
Ligelizumab + OmalizumabNovartisPhase 3
40
Ligelizumab + PlaceboNovartisPhase 1
21
OmalizumabNovartisPhase 2
35
canakinumabNovartisPhase 2
35
LOU064NovartisPhase 2
35
Omalizumab (Xolair) + PlaceboNovartisPhase 2/3
38
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo armNovartisPhase 2
35
LOU064 (blinded) + placeboNovartisPhase 3
47
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injectionNovartisPhase 3
47